WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Wednesday reported a loss of $25.5 million in its fourth quarter.
The Waltham, Massachusetts-based company said it had a loss of 46 cents per share. Earnings, adjusted to extinguish debt and for pretax expenses, were 33 cents per share.
The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 34 cents per share.
The drug developer posted revenue of $155.7 million in the period, which also missed Street forecasts. Eight analysts surveyed by Zacks expected $155.9 million.
For the year, the company reported profit of $41.6 million, or 74 cents per share. Revenue was reported as $638.8 million.
Repligen expects full-year earnings in the range of $1.42 to $1.49 per share, with revenue in the range of $620 million to $650 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGEN at https://www.zacks.com/ap/RGEN
